Business Outlook
The Company expects net revenues for the full year of 2022 to be in the range of RMB7,250 million to RMB7,550 million, and adjusted EBITDA to be in the range of RMB1,800 million to RMB1,950 million.
Cortexyme Reports Its Atuzaginstat Slowed Cognitive Decline In Participants With Alzheimer’s, P. Gingivalis Infection In Phase 2/3 Trial
Evidence supports P. gingivalis as a driver of Alzheimer’s in easily identified patient population
Successful identification of target population and therapeutic dose inform next steps
SOUTH SAN FRANCISCO,
